Prevalence of age-related macular degeneration in the United States - PubMed (original) (raw)
Prevalence of age-related macular degeneration in the United States
David S Friedman et al. Arch Ophthalmol. 2004 Apr.
Erratum in
- Arch Ophthalmol. 2011 Sep;129(9):1188
Abstract
Objective: To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender.
Methods: Summary prevalence estimates of drusen 125 microm or larger, neovascular AMD, and geographic atrophy were prepared separately for black and white persons in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US Census data and to projected US population figures for 2020 to estimate the number of the US population with drusen and AMD.
Results: The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy. More than 7 million individuals had drusen measuring 125 microm or larger and were, therefore, at substantial risk of developing AMD. Owing to the rapidly aging population, the number of persons having AMD will increase by 50% to 2.95 million in 2020. Age-related macular degeneration was far more prevalent among white than among black persons.
Conclusion: Age-related macular degeneration affects more than 1.75 million individuals in the United States. Owing to the rapid aging of the US population, this number will increase to almost 3 million by 2020.
Comment in
- Age-related macular degeneration is the leading cause of blindness..
Bressler NM. Bressler NM. JAMA. 2004 Apr 21;291(15):1900-1. doi: 10.1001/jama.291.15.1900. JAMA. 2004. PMID: 15108691 No abstract available.
Similar articles
- Prevalence of open-angle glaucoma among adults in the United States.
Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, Leske MC, Mitchell P, Congdon N, Kempen J; Eye Diseases Prevalence Research Group. Friedman DS, et al. Arch Ophthalmol. 2004 Apr;122(4):532-8. doi: 10.1001/archopht.122.4.532. Arch Ophthalmol. 2004. PMID: 15078671 Free PMC article. - Causes and prevalence of visual impairment among adults in the United States.
Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Congdon N, et al. Arch Ophthalmol. 2004 Apr;122(4):477-85. doi: 10.1001/archopht.122.4.477. Arch Ophthalmol. 2004. PMID: 15078664 - Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project.
Bressler SB, Muñoz B, Solomon SD, West SK; Salisbury Eye Evaluation (SEE) Study Team. Bressler SB, et al. Arch Ophthalmol. 2008 Feb;126(2):241-5. doi: 10.1001/archophthalmol.2007.53. Arch Ophthalmol. 2008. PMID: 18268216 - Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis.
Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Rudnicka AR, et al. Ophthalmology. 2012 Mar;119(3):571-80. doi: 10.1016/j.ophtha.2011.09.027. Epub 2011 Dec 15. Ophthalmology. 2012. PMID: 22176800 Review. - Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis.
Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, Cook DG, Owen CG. Rudnicka AR, et al. Am J Ophthalmol. 2015 Jul;160(1):85-93.e3. doi: 10.1016/j.ajo.2015.04.003. Epub 2015 Apr 6. Am J Ophthalmol. 2015. PMID: 25857680 Review.
Cited by
- Levodopa is associated with reduced development of new-onset geographic atrophy in patients with age-related macular degeneration.
Chan KS, Aggarwal N, Lawson S, Boucher N, MacCumber MW, Lavine JA. Chan KS, et al. Eye Vis (Lond). 2024 Nov 6;11(1):44. doi: 10.1186/s40662-024-00412-2. Eye Vis (Lond). 2024. PMID: 39501348 Free PMC article. - Role of Gonadal Steroid Hormones in the Eye: Therapeutic Implications.
Valero-Ochando J, Cantó A, López-Pedrajas R, Almansa I, Miranda M. Valero-Ochando J, et al. Biomolecules. 2024 Oct 7;14(10):1262. doi: 10.3390/biom14101262. Biomolecules. 2024. PMID: 39456195 Free PMC article. Review. - Clustered ARPE-19 cells distinct in mitochondrial membrane potential may play a pivotal role in cell differentiation.
Miyatani T, Tanaka H, Numa K, Uehara A, Otsuki Y, Hamuro J, Kinoshita S, Sotozono C. Miyatani T, et al. Sci Rep. 2024 Sep 27;14(1):22391. doi: 10.1038/s41598-024-73145-w. Sci Rep. 2024. PMID: 39333742 Free PMC article. - Gut microbiota and eye diseases: A review.
Zhao Y, Qiu P, Shen T. Zhao Y, et al. Medicine (Baltimore). 2024 Sep 27;103(39):e39866. doi: 10.1097/MD.0000000000039866. Medicine (Baltimore). 2024. PMID: 39331938 Free PMC article. Review. - Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial.
Barakat MR, Brown D, Hu A, Khurana RN, Marcus D, Pearlman J, Wykoff CC, Kapik B, Ciulla T. Barakat MR, et al. Ophthalmol Sci. 2024 Jul 25;5(1):100586. doi: 10.1016/j.xops.2024.100586. eCollection 2025 Jan-Feb. Ophthalmol Sci. 2024. PMID: 39328827 Free PMC article.
MeSH terms
Grants and funding
- R01 EY013460/EY/NEI NIH HHS/United States
- R01 EY013460-01/EY/NEI NIH HHS/United States
- R01 EY013460-02/EY/NEI NIH HHS/United States
- R01 EY013460-03/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical